A study in patients with SMA showed SPINRAZA® (nusinersen)
Achieved meaningful results across
age
groups—from infants to
adults1-3
Backed by the longest clinical trial
program to date in infants and
children.4 Supported by extensive
real-world evidence in
adults, teens,
and older children2,3,5
Click the tabs to see the data in the selected population
Pivotal trial: CHERISH1,6
The efficacy of SPINRAZA Low Dose Regimen (12mg loading doses/12 mg Maintenance doses) for later-onset SMA was demonstrated in CHERISH, a phase 3, sham-controlled pivotal trial. Study duration was 15 months and included 126 patients aged 2 to 9 years at screening.
- Primary outcome measured: Least-squares mean change from baseline in motor function as measured by HFMSE at 15 months
- Results: SPINRAZA: 3.9-point change; untreated: -1.0-point change
- The most common adverse reactions were fever, vomiting, headache, and back pain
HFMSE, Hammersmith Functional Motor Scale—Expanded; SMA, spinal muscular atrophy.
Extensive real-world
evidence in SMA2,3,5
A growing body of real-world
evidence supports the use of
Low Dose SPINRAZA in adults, teens, and older children2,3,5
Biogen-sponsored pivotal trials for
Low Dose SPINRAZA did not include adults
with SMA.
Click on the studies below for more.
| Publication | Study description | Population | Study duration |
|---|---|---|---|
|
Hagenacker T, et al5
Advances in Therapy. 2025;42(9):4143-4160 |
A systematic literature review (SLR) and meta-analysis of long-term nusinersen effectiveness |
1189 patients
|
Up to 57 months |
|
Günther R, et al3
The Lancet Regional Health—Europe. 2024;39:100862 |
An independent, prospective, observational multicenter study in Austria, Germany, and Switzerland |
347 patients
|
Up to 38 months |
|
Łusakowska A, et al2
Orphanet Journal of Rare Diseases. 2023;18(1):230 |
A prospective, observational study at 2 centers in Poland (sponsored by Biogen) |
120 patients
|
Up to 30 months |
Click the arrow for each study below to expand or close.
Hagenacker et al
Advances in Therapy
Systematic review and meta-analysis of long-term (up to 4 years) nusinersen effectiveness in adolescents and adults with spinal muscular atrophy5
Design: A systematic literature review (SLR) was conducted to identify recently published studies assessing the efficacy and effectiveness of long-term nusinersen treatment (12 mg loading doses/12 mg maintenance doses) in adolescents and adults with SMA. Seventeen recent studies were included in this SLR and considered along with 14 studies from a previous SLR for inclusion in the meta-analysis. Of the 31 eligible studies from the combined SLRs, 21 met the meta-analysis inclusion criteria. Studies were included in the meta-analysis if the following were available from the published results5:
- Mean change from baseline and standard deviations in HFMSE, RULM, and 6MWT at specific time
points, or - Percentage of patients with clinically meaningful improvement in the HFMSE, RULM, and 6MWT
Endpoints: For the meta-analysis, patient outcomes on the HFMSE, RULM, and 6MWT were combined across studies to determine the effects of nusinersen treatment on these motor function scales5:
- Mean HFMSE, RULM, and 6MWT changes from baseline over time, and
- Percentage of patients with clinically meaningful responses to nusinersen treatment over time, defined as:
Safety: Safety was not examined as part of the SLR and meta-analysis.
Review the Warnings and Precautions, including thrombocytopenia, coagulation abnormalities, and
renal toxicity here.
Meta-analysis statistical methods:
- Random-effects models with inverse variance method were used to pool effect sizes across studies5
- Time points were grouped in 1-year intervals to account for differences in the timing of assessments across studies (eg, <1 year, ≥1 and <2 years, ≥2 and <3 years, ≥3 and <4 years from baseline/nusinersen initiation)5
- Heterogeneity between publications was examined using the /2 statistic, which measures the proportion of the total variance that can be explained by between-study variance5
Limitations5:
- Sources of heterogeneity in the included studies could not be examined because of the use of aggregated published data
- Not all studies included in the updated SLR had long-term follow-up data. Fewer studies had follow-up beyond 3 years, and only 2 could be included in the meta-analysis at the last time point
- While the pooled meta-analysis showed mean improvements, some patients may not have experienced treatment benefits
- Age at treatment initiation was not examined as a factor in this meta-analysis
- All included studies were observational studies without a randomized controlled group and were subject to potential bias and confounding
- Results across time points cannot be directly compared because different studies (and thus, different patients) are captured at each time point in the meta-analysis
This study was supported by Biogen.
6MWT, 6-minute walk test; HFMSE, Hammersmith Functional Motor Scale—Expanded; RULM, Revised Upper Limb Module; SMA, spinal muscular atrophy.
Findings from the meta-analysis
Increases from baseline observed in HFMSE5
Figures below summarize the pooled estimates and corresponding 95% confidence intervals from select models (conducted in 1-year intervals) completed for the meta-analysis.
Pooled estimate (95% CI) percentage of patients with clinically meaningful HFMSE response.
Adapted from Hagenacker T, et al. Adv Ther. 2025.
>29% of patients experienced clinically meaningful improvement from baseline in HFMSE at each time point5
Results across time points cannot be directly compared because different studies (and thus, different patients) are captured at each time point in the meta-analysis.
Increases from baseline observed in RULM5
Figures below summarize the pooled estimates and corresponding 95% confidence intervals from select models (conducted in 1-year intervals) completed for the meta-analysis.
Pooled estimate (95% CI) percentage of patients with clinically meaningful RULM response.
Adapted from Hagenacker T, et al. Adv Ther. 2025.
More than a quarter of patients (>25%) experienced clinically meaningful improvement from baseline in RULM at each time point5
Results across time points cannot be directly compared because different studies (and thus, different patients) are captured at each time point in the meta-analysis.
Increases from baseline observed in 6MWT5
Figures below summarize the pooled estimates and corresponding 95% confidence intervals from select models (conducted in 1-year intervals) completed for the meta-analysis.
Pooled estimate (95% CI) percentage of patients with clinically meaningful RULM response.
Adapted from Hagenacker T, et al. Adv Ther. 2025.
>44% of patients experienced clinically meaningful improvements in 6MWT at each time point5
Results across time points cannot be directly compared because different studies (and thus, different patients) are captured at each time point in the meta-analysis.
Günther et al The Lancet
Regional Health—Europe
Long-term outcomes with SPINRAZA: a real-world study of adults and teens across multiple measures of motor function for up to 38 months3
Study design: An independent, prospective, observational study that assessed 237 adult and teen patients with genetically-confirmed 5q-associated SMA who were treated with SPINRAZA (12 mg loading doses/12 mg maintenance doses) for up to 38 months. Patients from the SMArtCARE registry were recruited between July 2017 and May 2022 in Germany, Switzerland, and Austria. Thirty-one patients were excluded due to insufficient follow-up and 11 discontinued SPINRAZA before completing the 14-month follow-up. Patients with missing data points were excluded from analysis.3
Please refer to the FDA-approved dosing schedule in the US Prescribing Information.
Study limitations3:
- Observational study without an untreated control group; this does not have the same class of evidence as a randomized, controlled trial
- Patient enrollment was limited to centers in Germany, Switzerland, and Austria. Treatment practices may vary by country
- Hammersmith Functional Motor Scale—Expanded (HFMSE) score interpretation is limited by floor effects in severely disabled patients (SMA type 2 and nonambulatory SMA type 3), which may have affected the results of the study
- Revised Upper Limb Module (RULM) score interpretation is limited by ceiling effects in less impaired patients (ambulatory SMA type 3), which may have affected the results of the study
- Motor assessments did not evaluate muscles required for swallowing or respiratory function
- Differences in loading dosing compared to approved SPINRAZA dosing schedule
Endpoints: Three functional outcomes were assessed at 14, 26, and 38 months of treatment and included 237, 171, and 120 patients, respectively3:
- HFMSE
- Primary endpoint: Mean change vs baseline
- Clinically meaningful improvement (defined as a change of ≥3 points)
- RULM
- Mean change vs baseline
- Clinically meaningful improvement (defined as a change of ≥2 points)
- 6MWT in ambulatory patients
- Mean change vs baseline
- Clinically meaningful improvement (increase in walking distance by ≥30 meters)
Safety: The safety was generally consistent with the known safety of SPINRAZA in clinical trials.1,3,6
- Safety was evaluated in 389 patients screened who had received at least one injection3
- 732 adverse drug reactions or procedure-related complications were documented in 91% of patients (n=353/389)
- 26% of patients (n=103/389) reported no adverse drug reactions; 64% of patients (n=250/389) reported at least 1 adverse reaction
- Most adverse reactions were post-lumbar puncture syndrome, headache, back pain, and infections
This registry was funded in part by Biogen.
6MWT, 6-minute walk test; FDA, Food and Drug Administration; HFSME, Hammersmith Functional Motor Scale—Expanded; RULM, Revised Upper Limb Module; SMA, spinal muscular atrophy.
Primary endpoint: Change in HFMSE score from baseline
Long-term outcomes with SPINRAZA:
HFMSE, RULM, and 6MWT3
Increase in mean HFMSE score vs baseline at each assessment3
*At baseline 2 patients had a full score (66 points) and 55 patients scored 0 points.
Proportion of patients with clinically meaningful change† in HFMSE score vs baseline up to 38 months
28 of the 68 patients with clinically meaningful increase at 14 months maintained this result for ≥38 months3
- HFMSE interpretation may have been limited by floor effects; non-ambulatory patients could not perform some of the activities assessed by HFMSE, leading to lower achievable scores
†Defined in the study as a score change of at least 3 points.
CI, confidence interval; SD, standard deviation.
RULM scores increased from baseline at each assessment3
Mean increase in RULM from baseline
‡At baseline 74 patients had a full score (37 points) and 17 patients scored 0 points.
Proportion of patients with clinically meaningful change§ in RULM score vs baseline up to 38 months
37% of patients (n=25/68) with clinically meaningful increase in RULM score at 14 months maintained this result at 38 months3
- RULM interpretation in ambulatory patients may have been limited by ceiling effects, which may have affected the results of the study
§Defined in the study as a score change of at least 2 points.
Increases in mean walking distance from baseline in the 6MWT at each assessment in ambulatory patients3
Mean improvement in walking distance (in meters) from baseline
Proportion of patients with clinically meaningful change|| in 6MWT score vs baseline up to 38 months
At 38 months, the mean increase in walking distance in the 6MWT from baseline was 32.20 meters3
||Defined in the study as a distance change of at least 30 meters.
Exploratory subgroup analysis in ambulatory and non-ambulatory patients3¶
Mean increase in HFMSE and RULM score from baseline
Regardless of ambulatory status, increases in mean HFMSE and RULM scores were reported with SPINRAZA3
- HFMSE score interpretation in non-ambulatory patients may have been limited by floor effects; non-ambulatory patients could not perform some of the activities assessed by HFMSE, leading to lower achievable scores. RULM score interpretation in ambulatory patients may have been limited by ceiling effects, which may have affected the results of the study
¶Additional subgroups were reported in the study.
Long-term outcomes with SPINRAZA: This real-world evidence informs on the safety and efficacy of long-term SPINRAZA treatment for up to 38 months in adults and teens with SMA3
Review the Warnings and Precautions, including thrombocytopenia, coagulation abnormalities, and renal toxicity1
Łusakowska et al Orphanet
Journal of Rare Diseases
This real-world evidence study in older children and adults on SPINRAZA evaluated functional assessments and patient-reported outcomes for up to 30 months2
Study design2: Prospective, observational study that assessed 130 patients who were treated with SPINRAZA (12 mg loading doses/12 mg maintenance doses) between March 2019 and January 2022 with SMA (types 1c-3), at 2 centers in Poland. Final analysis included 120 treatment-naïve patients. Seven patients were excluded due to insufficient follow-up, and 3 discontinued, which includes a fatality that was considered unrelated to treatment.2
Study limitations2:
- Open-label, multicenter study in Poland without a control group
- Treatment practices may vary by country
- Number of patients with type 1c and type 2 were limited
- Data for later time points were limited, as many patients had not yet reached those time points
- Missing assessments on some endpoints (eg, 6MWT) due to COVID-19 restrictions
- CHOP INTEND is not validated in adults
- Differences in dosing compared to approved Low Dose SPINRAZA dosing schedule
- PGI-I is subjective, patient-reported, and not validated in SMA
Endpoints2:
- Mean change in HFMSE vs baseline up to 30 months
- Mean change in CHOP INTEND score between month 0 and month 26
- Mean change in RULM score vs baseline up to 30 months
- Mean change in 6MWT score vs baseline up to 30 months
- PGI-I assessment at subsequent time points of treatment
Safety: The study safety profile is generally consistent with the safety reported in the SPINRAZA clinical trials1,2
- The most frequent adverse event was post-lumbar puncture syndrome (PLPS), reported in 198 patients (19%)2
- All patients with PLPS reported headache, mainly of mild intensity2
- Cerebrospinal fluid leak was observed after CT-guided injection at month 10 for 1 patient2
- The leak stopped within 1 hour without intervention2
In this real-world study, there were 1,023 intrathecal administrations and no administration failures2
Study was funded by a grant from Biogen.2
In the observational study, mean HFMSE score increased compared with baseline at each time point2
HFMSE patient population (n=73#):
- Mean age: 31 years (SD, 15.6 years; range, 5-66 years)
- Mean disease duration: 23.7 years (SD, 14 years; range, 4-62 years)
- SMA Type 2: 6 patients (4 children)
- SMA Type 3: 67 patients (10 children)
RESULTS:
- Mean HFMSE score increase of 5.1 points at month 30 (n=28)
Mean change in HFMSE vs baseline up to 30 months
In the study, a ≥3-point improvement was considered a clinically meaningful change
Proportion of patients who showed increase, no change, or decline in HFMSE score vs baseline up to 30 months
- In 15% of patients (11/73), the HFMSE score improved by ≥10 points during the study
#One patient with SMA type 2 did not undergo assessment at day 180 (month 6) but was assessed at the subsequent 4 time points. Therefore, he was included in the analysis. At month 30, 28 patients were evaluated using the HFMSE.
At month 30, the HFMSE score showed increase or no change in 96% of patients (27/28) on treatment with SPINRAZA2
Mean CHOP INTEND score increased compared with baseline at each time point2
CHOP INTEND patient population (n=47** ):
- Mean age: 33.7 years (SD, 11.0; range, 13-66 years)
- Mean disease duration: 31.7 years (SD, 9.5; range, 3.0-58.0 years)
- SMA type 1: 12 patients††
- SMA type 2: 13 patients
- SMA type 3: 22 patients
RESULTS:
- Mean CHOP INTEND score increased by 5.6 points at month 26 vs baseline
- Clinically meaningful improvements (≥4 points) in the CHOP INTEND score were seen in 20.5% of patients (9/44) at month 6 and in 65% of patients (11/17) at month 26
Mean change in CHOP INTEND score between month 0 and month 26††
- 5 patients were available for assessment at month 30; the mean difference was 9.4 points
The CHOP-ATTEND test validated for adult patients with severe symptoms was not available at the time of the study. For this reason, the CHOP INTEND test, which is not validated in adults, was used.
** Forty-four patients were assessed at least twice (at month 0 and month 6).
††Baseline CHOP INTEND score was not available for 3 adults with SMA Type 1 who started treatment abroad within the Expanded Access Program (EAP). They started study evaluation at month 10, month 14, and month 18, respectively. Assessment was available up to month 30 for 2 of these patients.
‡‡Low patient numbers (n=5) at 30 months preclude meaningful interpretation at this time point.
94% of patients (16/17) noted increases by at least 1 point at month 26 vs baseline2
RULM score increased compared with baseline at each time point2
RULM patient population (n=51):
- Mean age: 27 years (SD, 14; range, 5-66 years)
- Mean disease duration: 22 years (SD, 12.8; range, 3.8-62.0 years)
- SMA type 2: 9 patients
- SMA type 3: 43 patients
RESULTS:
- Mean RULM score increased by 1.96 points at month 30 vs baseline
Mean change in RULM score vs baseline up to 30 months
Proportion of patients who showed increase, no change, or decline in RULM vs baseline up to 30 months
- During treatment, the proportion of patients who showed increase in upper limb function was 61% (14/23) at month 30
Clinically meaningful improvements (≥2 points) in RULM score was seen in 43.5% (10/23) of patients at month 302
Mean 6MWT scores increased at each time point2
6MWT patient population (n=27 §§):
- Mean age: 27 years (SD, 13; range, 6-59 years)
- Mean disease duration: 18 years (SD, 10; range, 4-33 years)
- SMA type 3: 27 patients
RESULTS:
- Mean 6MWT increased by 27.0 meters at month 30 vs baseline
Mean change in 6MWT vs baseline up to 30 months
Proportion of patients who showed increase, no change, or decline in 6MWT score vs baseline up to 30 months
- A relatively large number of patients experienced worsening in each point of treatment: 40% of patients (6/15) at month 6 and 33% of patients (4/12) at month 30
§§The lack of a fairly significant number of ratings in the 6MWT was mainly due to patients’ fear of staying too long in the hospital and contacting medical staff and other patients during the pandemic.
Clinically meaningful improvement (≥30 meters increase in walking distance) was observed in 33% of patients (5/15) at month 6 and was 50% (6/12) at month 302
Increases were seen across all functional assessments up to 30 months2
Distribution of patients who achieved a clinically meaningful improvement in each of the functional tests
- Clinically meaningful improvement was defined as a change in HFMSE score of ≥3 points, change in CHOP INTEND score of ≥4 points, and change in RULM score of ≥2 points. For patients able to walk independently, significant improvement in the 6MWT score was defined as an increase in walking distance by at least 30 meters
||||Three patients who did not undergo assessment at month 0 were excluded. Only 5 patients were evaluated for CHOP INTEND at month 30.
Patients and caregivers assessed and self-reported their status, and most reported increase or no change while on treatment2¶¶
- While no patients reported feeling much worse or very much worse at each time point, between 2 and 5 patients reported feeling minimally worse at various time points during the study
¶¶PGI-I data was subjective and patient-reported.
6MWT, 6-minute walk test; CHOP-ATTEND, Children’s Hospital of Philadelphia Test of Attentive Endurance for Neuromuscular Disorders; CHOP INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; COVID-19, coronavirus disease 2019; CT, computed tomography; HFMSE, Hammersmith Functional Motor Scale–Expanded; PGI-I, Patient Global Impression-Improvement; RULM, Revised Upper Limb Module; SD, standard deviation; SMA, spinal muscular atrophy.
After 26 months of SPINRAZA treatment, 96.5% of patients (62/64) reported subjective increase or no change, which was also reported at month 30 in 100% (47/47) of the patients2